What did Geron Corporation (Gern) announce?
Geron Corporation (GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 200,000 shares of Geron common stock as inducements to three newly-hired employees in connection with commencement of employment with the Company. The stock options were granted on October 16,...
What are analysts' target prices for Geron's (Gern) stock?
5 equities research analysts have issued twelve-month target prices for Geron's stock. Their predictions range from $3.00 to $4.50. On average, they expect Geron's stock price to reach $3.90 in the next year.
Where can I buy Geron shares?
Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Geron's stock price today?
Is Gern stock worth $50 after FDA approval?
DNDN even went from $2 to $50 in a few short weeks after the FDA approved DNDN drug and GERN's drug technology is light years ahead of DNDN's drug. The FDA, the EU and the UK have all given GERN's drug fast track status. Just GERN's cash in the bank is worth over half of GERN's current stock price.
See more
Is Geron a good stock to buy?
Geron has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Should I buy GERN stock?
Geron Stock Forecast FAQ. Is Geron Stock a good buy in 2022, according to Wall Street analysts? The consensus among 1 Wall Street analyst covering (NASDAQ: GERN) stock is to Buy GERN stock.
Who owns Geron?
Geron is not owned by hedge funds. The company's largest shareholder is RA Capital Management, L.P., with ownership of 9.4%. For context, the second largest shareholder holds about 7.9% of the shares outstanding, followed by an ownership of 4.8% by the third-largest shareholder.
What is the price forecast for GERN?
The 4 analysts offering 12-month price forecasts for Geron Corp have a median target of 3.50, with a high estimate of 7.00 and a low estimate of 2.00. The median estimate represents a +92.31% increase from the last price of 1.82.
What does Geron Corporation do?
Geron Corporation is a biotechnology company located in Foster City, California, which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase.
Is imetelstat FDA approved?
The FDA has granted a fast track designation to imetelstat for the treatment of adult patients with relapsed or refractory myelofibrosis (MF) who have intermediate-2 or high-risk disease.
What is a Geron?
Geron, an elder (from the Greek "γέρων") of an Orthodox monastery (starets in Russian)
What does Geron make?
Corporate Profile. Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, with disease modification potential for myeloid hematologic malignancies.
Nasdaq Global Select
Environmental, Social, and Governance Rating
A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS.
Business Summary
"B" score indicates good relative ESG performance and an above-average degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
What is Geron Corp?
A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS.
What time does Old Dominion stock trade?
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron po
Does market cap include convertible securities?
Old Dominion Freight Line, Inc. Common Stock. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4 :00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these sessions may offer less liquidity and inferior prices.
Geron (NASDAQ:GERN) Price Target and Consensus Rating
It does not include securities convertible into the common equity securities. "Market Cap" is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable).
Analyst Price Target Consensus
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy).
Analyst Ratings By Month
Sign-up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter.
Average Share Price and Price Target by Month
The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Geron (NASDAQ:GERN) Analyst Ratings Frequently Asked Questions
The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target.
Release
Risks
- 4 brokers have issued 12 month target prices for Geron's shares. Their predictions range from $1.80 to $4.00. On average, they anticipate Geron's share price to reach $3.0125 in the next twelve months. This suggests a possible upside of 73.1% from the stock's current price. View Analyst Price Targets for Geron.
Ratings
- 4 Wall Street analysts have issued \"buy,\" \"hold,\" and \"sell\" ratings for Geron in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of \"Buy.\" View Analyst Ratings for Geron.
Reception
- News coverage about GERN stock has been trending negative this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Gero…
Ownership
- Geron saw a increase in short interest in the month of April. As of April 15th, there was short interest totalling 42,790,023 shares, an increase of 0.6% from the March 29th total of 43,065,652 shares. Based on an average trading volume of 4,045,055 shares, the short-interest ratio is presently 10.6 days. Currently, 23.1% of the shares of the stock are sold short. View Geron's Curr…
Business
- Geron has a market capitalization of $324.54 million and generates $1.07 million in revenue each year. The biopharmaceutical company earns $-27,020,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. Geron employs 17 workers across the globe.
Location
- Geron's mailing address is 149 COMMONWEALTH DRIVE SUITE 2070, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected].